June 27, 2016
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, […]
News, research & analysis from the global Life Sciences and related industries.